This is a thread to help with the evaluation of Robuvit for ME/CFS. We already have a number of threads for individual scientific papers on Robuvit, mostly for conditions other than ME/CFS. Hopefully, this one can serve to consolidate the discussion.
2020 paper of 40 otherwise healthy older men who complained of decreased vigor. Claims of improvements and reductions in oxidative stress. No mention of blinding in the abstract. Mentions that it has previously been shown to be effective in chronic fatigue syndrome.
Exploring the concept of vigor and dysvigor in men of 50-65 years: effects of Robuvit®, 2020, Ledda, Belcaro et al
2018 PTSD treatment study of 18 women given psychological therapy and 16 women given psychological therapy plus Robuvit. Open label trial. The abstract reports that Robuvit cohort improved more than the cohort with psychological therapies alone.
Supplementation with Robuvit® in post-traumatic stress disorders associated to high oxidative stress, 2018, Belcaro et al
2018 Fatigue in convalescence study. No mention of sample size in the abstract but it is noted that it is a preliminary study. Claims a wide range of improvements in the Robuvit group compared to the standard management group.
Claims Robuvit has been successfully used in hepatic failure and in CFS.
Robuvit®: improvement of fatigue in medical convalescence, 2018, Belcaro et al
2020 paper of 40 otherwise healthy older men who complained of decreased vigor. Claims of improvements and reductions in oxidative stress. No mention of blinding in the abstract. Mentions that it has previously been shown to be effective in chronic fatigue syndrome.
Exploring the concept of vigor and dysvigor in men of 50-65 years: effects of Robuvit®, 2020, Ledda, Belcaro et al
2018 PTSD treatment study of 18 women given psychological therapy and 16 women given psychological therapy plus Robuvit. Open label trial. The abstract reports that Robuvit cohort improved more than the cohort with psychological therapies alone.
Supplementation with Robuvit® in post-traumatic stress disorders associated to high oxidative stress, 2018, Belcaro et al
2018 Fatigue in convalescence study. No mention of sample size in the abstract but it is noted that it is a preliminary study. Claims a wide range of improvements in the Robuvit group compared to the standard management group.
Claims Robuvit has been successfully used in hepatic failure and in CFS.
Robuvit®: improvement of fatigue in medical convalescence, 2018, Belcaro et al
Last edited: